Dechert LLP represented Allergopharma, the Merck Business Unit Allergy, in its recently announced exclusive licensing agreement with S-TARget therapeutics (S-Target), an Austrian biotechnology company which develops therapeutic preparations for all forms of allergies. The focus of this cooperative agreement is the use of S-TARget S-TIR™ technology and the associated development of a new generation of products for the casual treatment of allergies. Terms of the agreement and financial details are confidential.

Allergopharma was founded in 1969 and since 2013 has been an integrated part of Merck as the Business Unit Allergy. The unit is primarily based on hypoallergenic, high-dose preparations which can be used pre-seasonally or throughout the year.

Dr. Rüdiger Herrmann and Dr. Monika Richter, who joined Dechert’s Life Sciences group in Frankfurt this past year, provided counsel to Allergopharma on this matter.